TR200003779T2 - Transkripsiyon faktörü NF-kB inhibitörleri - Google Patents

Transkripsiyon faktörü NF-kB inhibitörleri

Info

Publication number
TR200003779T2
TR200003779T2 TR2000/03779T TR200003779T TR200003779T2 TR 200003779 T2 TR200003779 T2 TR 200003779T2 TR 2000/03779 T TR2000/03779 T TR 2000/03779T TR 200003779 T TR200003779 T TR 200003779T TR 200003779 T2 TR200003779 T2 TR 200003779T2
Authority
TR
Turkey
Prior art keywords
inhibitors
disease
diseases
amino
transcription factor
Prior art date
Application number
TR2000/03779T
Other languages
English (en)
Inventor
Francis Callahan James
C.Chabot-Fletcher Marie
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200003779T2 publication Critical patent/TR200003779T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Bu bulus, trankripsiyon faktörü NF-kB nin farmasötik olarak kabul edilebilir tuzlari, hidratlari ve solventlerinin amino-indanon inhibitörlerini, bu bilesimlerin terkiplerini ve NF-kB aktivasyonunun rol oyandigi hastaliklari tedavi yöntemleri saglamaktadir. Bu bulus özellikle örnegin enflamatuar hastaliklarin, özellikle romatizmal artrit, enflamatuar barsak hastaligi, ve astim; sedef hastaligi ve atopik dermatil dahil, dermatoz; oto-immün hastaliklar; doku ve organ reddi; alzheimer hastaligi; felç; ateroskleroz; restenoz; kanser ve Hodojken hastaligi; bazi viral enfeksiyonlar, AIDS dahil; osteoartrit; osteoporoz; ve Ataxia Telangiestasia gibi NF-kB aktivasyonuyla baglantili çesitli hastaliklarin, ihtiyaci olan hastaya bir bulus bilesimi verilmesi için yöntemler saglar.
TR2000/03779T 1998-06-19 1999-06-18 Transkripsiyon faktörü NF-kB inhibitörleri TR200003779T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
TR200003779T2 true TR200003779T2 (tr) 2001-06-21

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03779T TR200003779T2 (tr) 1998-06-19 1999-06-18 Transkripsiyon faktörü NF-kB inhibitörleri

Country Status (17)

Country Link
EP (1) EP1085872A4 (tr)
JP (1) JP2002518333A (tr)
KR (1) KR20010052990A (tr)
CN (1) CN1306428A (tr)
AR (1) AR019871A1 (tr)
AU (1) AU4699699A (tr)
BR (1) BR9911151A (tr)
CA (1) CA2335293A1 (tr)
CO (1) CO5080752A1 (tr)
CZ (1) CZ20004760A3 (tr)
HU (1) HUP0102492A2 (tr)
IL (1) IL140324A0 (tr)
NO (1) NO20006452L (tr)
PL (1) PL345577A1 (tr)
TR (1) TR200003779T2 (tr)
WO (1) WO1999065495A1 (tr)
ZA (1) ZA200007448B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL150763A0 (en) * 2000-01-24 2003-02-12 Genzyme Corp Jak/stat inhibitors and pharmaceutical compositions containing the same
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1989203A2 (en) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
WO2011014825A2 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2012109527A2 (en) 2011-02-10 2012-08-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
JP2002518333A (ja) 2002-06-25
HUP0102492A2 (hu) 2001-11-28
NO20006452L (no) 2001-02-16
ZA200007448B (en) 2001-12-12
AR019871A1 (es) 2002-03-20
PL345577A1 (en) 2001-12-17
EP1085872A1 (en) 2001-03-28
CN1306428A (zh) 2001-08-01
AU4699699A (en) 2000-01-05
KR20010052990A (ko) 2001-06-25
CO5080752A1 (es) 2001-09-25
IL140324A0 (en) 2002-02-10
NO20006452D0 (no) 2000-12-18
BR9911151A (pt) 2001-03-06
CA2335293A1 (en) 1999-12-23
CZ20004760A3 (cs) 2001-08-15
WO1999065495A1 (en) 1999-12-23
EP1085872A4 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
TR200003781T2 (tr) Transkripsiyon faktörü NF- kB inhibitörleri
TR200003779T2 (tr) Transkripsiyon faktörü NF-kB inhibitörleri
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
PT1115701E (pt) Ureias de arilsulfonanilida
DE602005016718D1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
TR200102967T2 (tr) Substitüsyonlu azollar
MY138352A (en) Benzothiazole derivatives
NO995543D0 (no) Monoestere fra probucol for behandling av kardiovaskulaer og inflammatorisk sykdom
BR0111544A (pt) Heterociclos bicìclicos 6,5-fundidos
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
BRPI0415185A (pt) 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
TR200102131T2 (tr) Matrisk metaloproteinaz inhitörleri olarak 2,3,4,5-tetrahidro-1H[1,4] benzodiyazepin-3- hidroksamik asitler.
BR9908882A (pt) Bisindolimaleimidas substituìdas para a inibição de proliferação de célula
ATE380174T1 (de) Arginin-mimetika als faktor xa-inhibitoren
EA200000921A1 (ru) Антагонисты рецептора витронектина
DE60028253D1 (de) Neue purine
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
ATE248845T1 (de) Arylsulfonanilid-phosphate
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DK0804465T3 (da) Nye elastaseinhibitorer
BRPI0415355A (pt) triarilimidazóis